A prospective 3. 5 Year Drukker et al IJC 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734625/ March 2013 evaluation of the utility Prospective A prospective of the 70-gene signature observation evaluation of a breast to identify those breast study cancer prognosis cancer patients that signature in the may safely forgo observational RASTER chemotherapy. As compared to standard clincopathological classification, MammaPrint 20% of Clinical High Risk patients to Low risk. 97% of this Low Risk patient group which primarily chose to forgo chemotherapy, were disease free at 5 years.
3. 5 Year Prospective observation study Drukker et al IJC 2013. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER A prospective evaluation of the utility of the 70-gene signature to identify those breast cancer patients that may safely forgo chemotherapy. As compared to standard clincopathological classification, MammaPrint 20% of Clinical High Risk patients to Low risk. 97% of this Low Risk patient group which primarily chose to forgo chemotherapy, were disease free at 5 years. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734625/ March 2013
MSAC%20Application%201376.1_MammaPrint%20redacted.docx